NMRA Share Price Performance
US$1.60
0.33 (25.98%)
75.5% undervalued intrinsic discount
US$6.53
Fair Value
Price US$1.60
AnalystConsensusTarget US$6.53
AnalystHighTarget US$12.87
Fair ValueUS$6.53
Share Pricen/a
Narrative Update • Jul 10
Neumora Therapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
NMRA Community Narratives
AN
Fair Value
·Fair Value US$6.53 75.5% undervalued intrinsic discount
CNS And Obesity Pipeline Will Create Long Term Value As Late Stage Data Emerges
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$12.87 87.6% undervalued intrinsic discount
Multiple Late Stage Brain Disease Programs Will Drive Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CNS And Obesity Pipeline Will Create Long Term Value As Late Stage Data Emerges
Neumora Therapeutics is a drug developer with several late-stage programs aimed at common brain and metabolic conditions, and upcoming trial results could reshape how investors view its long-term potential. The catch is that it still brings in no sales, burns cash, and any safety or trial setbacks could force fundraising and slow its path toward real-world patients.Read more
AN
US$6.53
75.5% undervalued intrinsic discount
Fair Value
Profit Margin
19.4%
Future PE
127.1x
Price in 2029
US$0
Multiple Late Stage Brain Disease Programs Will Drive Long Term Upside Potential
Neumora is betting on a stack of late-stage brain disease programs, so one win could change the company’s future even if others miss. The flip side is long timelines and safety or trial setbacks that could force another cash raise before any drug reaches patients.Read more
AN
US$12.87
87.6% undervalued intrinsic discount
Fair Value
Profit Margin
19.65%
Future PE
113.9x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
NMRA: Early Neuroscience Pipeline Will Become Central Driver After Trial Setback
Fair Value: US$6.53 75.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NMRA: Early Pipeline And Cost Cuts Will Drive Future Rebound Potential
Fair Value: US$12.87 87.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Neumora Therapeutics, Inc. Key Details
About NMRA
- Founded
- 2019
- Employees
- 92
- CEO
- WebsiteView website
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company’s preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson’s Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Recent NMRA News & Updates
Narrative Update • Jun 26
